Inactive Instrument

News Impax Laboratories Inc Nasdaq

Equities

US45256B1017

Summary

Unlock all the news: Be the first to know and act before the market!

Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	Jul. 01	MT
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)	Jul. 01	BU
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar	Jul. 01	BU
Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar	Jul. 01	CI
Kashiv Biosciences Enters into Exclusive Licensing Agreement with Amneal Pharmaceuticals, Inc. for Commercialization of A Proposed Biosimilar to XOLAIR®	Jul. 01	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 3000 Growth Index	Jun. 30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 3000E Growth Index	Jun. 30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth Index	Jun. 30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2500 Growth Index	Jun. 30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Amneal Releases 2023 Environmental, Social and Governance Report	Jun. 28	BU
Transcript : Amneal Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:30 PM	Jun. 05
Amneal Pharmaceuticals : Jefferies Global Healthcare Conference 2024	Jun. 05	PU
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies	Jun. 05	BU
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies	Jun. 05	CI
Amneal Pharmaceuticals Begins Supplying Generic Version of Narcan	May. 22	DJ
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California	May. 22	BU
Amneal to Participate at Upcoming Investor Conference	May. 22	BU
Amneal Begins Supplying Over-The-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California	May. 22	CI
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	May. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Impax Laboratories Inc Nasdaq

Equities

US45256B1017

Summary

Filters